drugset / Trial / NCT01748747
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This pilot clinical trial studies vaccine therapy and resiquimod in treating patients with stage II-IV melanoma that has been removed by surgery. Vaccines made from peptides may help the body build an effective immune response to kill tumor cell tumor cells. Biological therapies, such as resiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. It is not yet known whether Gag:267-274 peptide vaccine and resiquimod are more effective when given together or separately
Timeline
- Start
- 2012-10
- Primary completion
- 2014-12-14
- Completion
- 2017-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gag:267-274 peptide vaccine | Vaccine | — | Subcutaneous |
| Subject | MART-1 antigen | Vaccine | — | Subcutaneous |
| Subject | Resiquimod | Small molecule | — | Topical |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | Subcutaneous |